contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-bico-q3-review-a-return-to-organic-growth-and-adjusted-ebitda-profitability

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

Bico Group Audiocast Q3/25:                   Inderes              BICO, Audiocast, Q3'25 - Inderes    Time: 2025-11-04 10:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference

Mattek ja Visikol myyntiin 80m$ 4x sales hintaan. En jaksa nyt kaivella mitä näistä maksettiin, mutta kuulostaa hyvältä. Melkonen sekoilu kyllä ollut tämän yhtiön matka covid kuplasta tänne. Hankitaan poskettomilla valuaatioilla ( toki onneksi osittain omia ylihintaisia osakkeita käyttäen) kaikenlaista tj:n visioihin sopivaa - ajetaan päin seinää korkojen noustessa ja nyt divestoidaan samat hankinnat pois.

Herätellään tämä ketju taas henkiin Bicon 2024 tulos on tullut ulos ja parin vuoden autiomaavalluksen jälkeen näyttää itse asiassa aika hyvältä. Tappio pienentynyt ratkaisevasti vuodesta 2023 ja Q4/2024 on ollut voitollinen kvartaali.   Lähde: Investors - BICO - The Bio Convergence Company Jos joku on vielä mukana, tästä voi kyyti vielä parantua oikein hyvin. Kyllä tämä Hesulin voittaa =)

Tätä heinäkuun alkupuolella julkaistua uutista tänne ei oltu vielä laitettukaan: Next step in Sartorius partnership finalized: several sub-sales and distribution agreements as well as R&D project agreements have been signed                   BICO              Single Press release    BICO enables and automates the life science lab of the future.         Est. reading time: 1 minute                               Eli touko-kesäkuussa ovat solmineet sopimuksia Sartoriuksen kanssa ja sen myötä kesäkuun alun jälkeen osakekurssi onkin noussut jo +30 %.

Dagens industri – 7 Jun 23              Kraschrisk i medicinteknikbolaget    Ensidigt fokus på tillväxt på bekostnad av den finansiella stabiliteten fick Viaplay- och SBB-aktierna på fall och tvingade bort bolagens vd:ar. Medicinteknikbolaget Bico kan vara näst på tur. Aktien går uselt och bolaget är ytterst bräckligt.                             Tässä ilmeisesti jotain juttua Bicosta, mutta näkyy vain tilaajille.

BICO - The Bio Convergence Company              Single Press release    BICO skapar framtiden för livräddande behandlingar genom att minska världens organbrist och påskynda läkemedelsutvecklingen.         Est. reading time: 1 minute                               Klo 7.00 julkaistu tilinpäätös. Mielenkiintoista nähdä mitä markkina tuumaa.

Holy shit. Klo 10 on tulossa turpajuhlat…

BICO Group

Redeye updates its estimates and fair value range following BICO’s Q3 2025 report showing a return to organic growth in line with our projections. It also showed a slight beat on sales and adjusted...

<div class="mfn-body"><p>Redeye updates its estimates and fair value range following BICO’s Q3 2025 report showing a return to organic growth in line with our projections. It also showed a slight beat on sales and adjusted EBITDA compared to our estimates, on account of stronger-than-anticipated Lab Automation sales. BICO trades at an EV/S of 0.5x and an EV/EBITDA of 12x on Redeye's 2026e projections.</p><p><a rel="noopener" href="https://www.redeye.se/research/1135204/bico-q3-review-a-return-to-organic-growth-and-adjusted-ebitda-profitability?utm_source=MFN&amp;utm_medium=pmcour">Read more and download the Research Update.</a><br>&nbsp;<br>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.<br>&nbsp;<br>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/627be576-5a13-42e2-b7da-22cadef75b51/bico-q3-review-a-return-to-organic-growth-and-adjusted-ebitda-profitability.pdf" class="mfn-generated mfn-primary">BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability</a></p></div>

Redeye: BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability

Redeye: BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability